Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ravenquest Biomed Inc RVVQF

Ravenquest BioMed Inc is a Canada-based diversified cannabis company with divisions focused upon cannabis production, management services and consulting and specialized research and development. It provides integrated solutions to companies in the cannabis industry and provides growing and drying technologies, patient and genetic management systems, and security management solutions The company operates through the following segments - Consulting business and Cultivation and Sale of Medical Cannabis.


GREY:RVVQF - Post by User

Post by ourrugon Nov 25, 2019 8:57pm
320 Views
Post# 30391639

Valour on Financing and Multi Revenue Channels (via ceo.ca)

Valour on Financing and Multi Revenue Channels (via ceo.ca)
“A lender doesn't directly care about the share price of a company, especially when it's in a highly volatile market. They are going to ascribe value to a) physical assets that they can claim in the event of a bankruptcy b) sellable goods and procedures that the assets can consistently produce, and c) the solvency and diversity of their sales channels.
 
RQB has two large operations that are sellable to another cannabis producer if absolutely necessary. They also have the IP generated at McGill University which will one day be pure cash flow, even if the market doesn't currently give value to it. They have a consistent and repeatable growing process that has received very high quality assessments from Health Canada, and they have a Diversified sales channel, including B2B and provinces in Canada, and B2B in Australia.
 
The market changes quickly and any participants appetite for risk can change overnight. If and when they finally get this debenture issue behind them, there is capital in the wings that would be willing to jump in. But until then, and with tax loss season in force, it's going to sit here.” 
 
See original post in context: https://ceo.ca/rqb?5255eb6d469c
 
<< Previous
Bullboard Posts
Next >>